| CDDO-TFEANrf2 activator |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity ≥ 95.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
CDDO-TFEA Dilution Calculator
calculate
CDDO-TFEA Molarity Calculator
calculate
| Cas No. | 932730-52-4 | SDF | Download SDF |
| Synonyms | CDDO-Trifluoethyl Amide,RTA 404,TP-500 | ||
| Chemical Name | 2-cyano-3,12-dioxo-N-(2,2,2-trifluoroethyl)-oleana-1,9(11)-dien-28-amide | ||
| Canonical SMILES | CC1(CC[C@@]2(CC[C@@](C)([C@@]3(CC[C@]4(C(C)(C(C(C#N)=C[C@@]4(C3=CC5=O)C)=O)C)[H])C)[C@]5([C@@]2(C1)[H])[H])C(NCC(F)(F)F)=O)C | ||
| Formula | C33H43F3N2O3 | M.Wt | 572.7 |
| Solubility | ≤5mg/ml in ethanol;5mg/ml in DMSO;5mg/ml in dimethyl formamide | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
CDDO-trifluoroethyl-amide (CDDO-TFEA), a trifluoroethylamide derivative of CDDO, is an Nrf2/ARE pathway activator [1][2][3].
The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway is an important pathway involved in antioxidant and anti-inflammatory responses. Modulation of the Nrf2/ARE pathway is an attractive therapeutic target for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Huntington"s disease (HD) [2][3].
CDDO-TFEA is an Nrf2/ARE pathway activator. In NSC-34 G93A SOD1 cells, CDDO-TFEA upregulated Nrf2 expression and caused translocation of Nrf2 into the nucleus. CDDO-TFEA also increased the expression of Nrf2/ARE-regulated proteins (NQO-1, HO-1 and Glutathione reductase).
In mice with experimental autoimmune encephalomyelitis (EAE), CDDO-TFEA reduced immune and inflammatory cell populations. CDDO-TFEA also significantly reduced Th1 and Th17 cytokines (IL6, IL17, IFNγ, TNFα and GMCSF) [1]. In ALS mice model, CDDO-TFEA upregulated the expression and resulted in translocation of Nrf2 to the nucleus of neurons in the spinal cord. In G93A SOD1 mice, CDDO-TFEA increased the life-span by 17.6 days [2].
References:[1]. Pareek TK, Belkadi A, Kesavapany S, et al. Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Sci Rep. 2011;1:201.[2]. Neymotin A, Calingasan NY, Wille E, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011 Jul 1;51(1):88-96.[3]. Stack C, Ho D, Wille E, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington"s disease. Free Radic Biol Med. 2010 Jul 15;49(2):147-58.
